

# Candidemia - Pipeline Insight - 2020

<https://marketpublishers.com/r/CA2358A2A556EN.html>

Date: November 2020

Pages: 40

Price: US\$ 1,500.00 (Single User License)

ID: CA2358A2A556EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Candidemia – Pipeline Insight, 2020," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Candidemia Understanding

#### Candidemia: Overview

Candidemia is defined as the presence of *Candida* species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. *Candida albicans* is the most common cause of candidemia, representing 35% to 60% of isolates. *Candida parapsilosis*, *Candida tropicalis*, *Candida glabrata* and *Candida krusei*, are the most common nonalbicans *Candida* species identified in cultures. Most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.

## Symptoms

The symptoms of Candidemia include:

Fever, chills

Skin rash

Generalized weakness or fatigue

Low blood pressure

Muscle aches

Vision changes or signs of an eye infection

Headaches and neurological deficits

Abdominal pain

## Diagnosis

Diagnosis of candidemia is based on direct fungal detection in blood cultures. The advantage of cultures is the ability to do susceptibility testing. Biopsy should be done in patients with localized findings and sent for culture and gram staining. The diagnosis can also be made by detecting antigens of *Candida* in the blood stream. New polymerase chain reaction tests are being developed and evaluated in clinical trials.

## Treatment

Early empiric antifungal therapy should be strongly considered in critically ill patients with risk factors for invasive candidiasis in whom the disease is suspected, as some studies have shown reduced mortality with this strategy. The decision to start therapy should be based on clinical suspicion, risk factors, and surrogate markers of candidemia (e.g., B-d-glucan). Empiric therapy should start with an echinocandin (caspofungin, micafungin, anidulafungin) as first choice therapy. Fluconazole may be considered in certain patients who are not critically ill and in whom susceptibility to fluconazole is likely. Amphotericin B can be given to patients with intolerance or contraindications to

other treatments. Transition to fluconazole is recommended for stable patients in whom cultures have resulted in sensitive *Candida* species, such as *C. albicans*.

## Candidemia Emerging Drugs Chapters

This segment of the Candidemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Candidemia Emerging Drugs

### Rezafungin acetate: Cidara Therapeutics

Rezafungin acetate is a drug that is a glucan synthase inhibitor. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics.

### Fosmanogepix: Amplyx Pharmaceuticals

Fosmanogepix has a novel mechanism of action that inhibits the highly conserved fungal enzyme Gwt1, which is essential for trafficking and anchoring mannoprotein to the outer cell wall in fungi. Fosmanogepix is currently in Phase 2 clinical trials evaluating the efficacy and safety of both intravenous (IV) and oral formulations for the treatment of patients with fungal infections caused by aspergillosis and candidemia, including candidemia caused by *C. auris*.

Further product details are provided in the report

## Candidemia: Therapeutic Assessment

This segment of the report provides insights about the different Candidemia drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Candidemia

There are approx. 3+ key companies which are developing the therapies for Candidemia. The companies which have their Candidemia drug candidates in the most advanced stage, i.e. phase III include, Cidara Therapeutics.

## Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Candidemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Candidemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidemia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The therapies under development are focused on novel approaches to treat/improve Candidemia.

Candidemia Report Insights

Candidemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Candidemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Candidemia drugs?

How many Candidemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Candidemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Candidemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Candidemia and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Cidara Therapeutics

Amplyx Pharmaceuticals

### Key Products

Rezafungin acetate

Fosmanogepix

## Contents

Introduction

Executive Summary

Candidemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Candidemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Candidemia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Candidemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Rezafungin acetate: Cidara Therapeutics

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Fosmanogepix: Amplyx Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)



Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report  
Inactive Products  
Comparative Analysis  
Candidemia Key Companies  
Candidemia Key Products  
Candidemia- Unmet Needs  
Candidemia- Market Drivers and Barriers  
Candidemia- Future Perspectives and Conclusion  
Candidemia Analyst Views  
Candidemia Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Candidemia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Candidemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Candidemia - Pipeline Insight - 2020

Product link: <https://marketpublishers.com/r/CA2358A2A556EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA2358A2A556EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970